Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation

Journal of Clinical Oncology

Volumn 18, Issue 15, 2000, Pages 2817-2827

  Katz, Angela ^a   Strom, Eric A ^a   Buchholz, Thomas A ^a   Thames, Howard D ^a   Smith, Cynthia D ^a   Jhingran, Anuja ^a   Hortobagyi, Gabriel ^a   Buzdar, Aman U ^a   Theriault, Richard ^a   Singletary, Eva S ^a   McNeese, McNeese ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME;

EID: 0033898756     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.15.2817     Document Type: Article

References (52)

1. Effects of radiotherapy and surgery in early breast cancer
2. The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II: The South Sweden Breast Cancer Trial
3. Adjuvant radiotherapy and chemotherapy in breast cancer
4. Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: A Southeastern Cancer Study Group (SEG) trial
5. Postoperative radiotherapy in breast cancer: Long term results from the Oslo study
6. The role of radiotherapy in the management of operable locally advanced breast carcinoma
7. Adjuvant radiation therapy versus surgery alone in operable breast cancer: Long-term follow-up of a randomized clinical trial
8. Evaluation of radiotherapy in high-risk breast cancer patients: Report from the Danish Breast Cancer Cooperative Group (DBCG 82) trial
9. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy
10. Postoperative radiotherapy in high-risk post menopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial
11. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
12. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy
13. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group
14. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
15. FAC + BCG as adjuvant therapy in breast cancer: An 8-year update
16. Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer: A prospective randomized trial
17. Results of adjuvant chemotherapy trials in breast cancer at MD Anderson Hospital and Tumor Institute
18. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs
19. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer
20. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer
21. Irradiation (XRT) following mastectomy in patients treated with FAC adjuvant therapy: M.D. Anderson Cancer Center experience
22. Overview of randomized trials comparing radical mastectomy without radiotherapy in breast cancer
23. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy
24. Postmastectomy radiation: Then and now
25. Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?
26. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicinftorafur) and tamoxifen in stage II breast cancer: Long-term follow-up results of a randomised trial
27. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: An intergroup study
28. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive nodes
29. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience
30. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy
31. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen versus tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer
32. Two months of doxorubicin- cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer patients with tamoxifen-nonresponsive tumors: Results of the National Surgical Adjuvant Breast and Bowel Project B-15
33. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
34. Cyclophosphamide, methotrexate, and fluorouracii with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes
35. A randomized trial of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer: Eleven year follow-up of a Piedmont Oncology Association trial
36. Local-regional recurrence in breast cancer after mastectomy and Adriamycin-based adjuvant chemotherapy: Evaluation of the role of postoperative radiotherapy
37. Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast carcinoma
38. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: Patterns and prognoses
39. Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer
40. Breast carcinoma: Pattern of recurrence and metastasis after mastectomy
41. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer
42. A controlled trial of extended radical versus radical mastectomy: Ten-year results
43. The conservative radical mastectomy of Patay: 10 year results in 425 patients
44. The influence of untreated internal mammary metastases upon the course of mammary cancer
45. Significance of internal mammary lymph node metastases in breast cancer
46. Inefficiency of internal mammary node dissection in breast cancer surgery
47. Improved methodology for analyzing local and distant recurrence
48. Analysis of the probability and risk of cause-specific survival
49. A note on estimating local recurrence rates in clinical trials on the treatment of breast cancer
50. Consensus statement on postmastectomy radiation therapy